首頁 > 市場調查報告書 > 製藥

婦科治療

市場調查報告書

商品編碼

1425123

全球子宮內膜異位症治療市場：預測（2024-2029）

Endometriosis Treatment Market - Forecasts from 2024 to 2029

出版日期: 2024年01月29日 | 出版商:

Knowledge Sourcing Intelligence | 英文 143 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

全球子宮內膜異位症治療市場規模預計將從2022年的14.31億美元成長到2029年的29.1億美元，複合年成長率為11.87%。

子宮內膜異位症是一種常見但令人痛苦的疾病，會干擾日常生活。當您患有子宮內膜異位症時，類似子宮內膜的組織會在骨盆和腹部周圍生長。除了引起生殖問題外，子宮內膜異位症還會導致疼痛和經期延長。藥物療法和手術通常用於治療子宮內膜異位症。

子宮內膜異位症盛行率增加

根據世界衛生組織 (WHO) 的數據，全球約有 10%（1.9 億人）的育齡婦女和青少年受到子宮內膜異位症的影響。骨盆腔極度不適是子宮內膜異位症的常見副作用，尤其是在月經期間。有些人在上廁所或做愛時也可能會感到疼痛。有很多人在懷孕方面遇到困難。子宮內膜異位症是一種複雜的疾病，影響著世界各地從初潮到閉經的許多女性，無論社會地位或文化背景如何。子宮內膜異位症的治療通常著重於症狀管理，因為目前尚無公認的治療方法。這導致了子宮內膜異位症治療行業的成長。

增加子宮內膜異位症意識計劃

各政府機構正在努力製定計劃，為人們提供有關子宮內膜異位症的必要知識。例如，ENPOWR計劃是 EndoFound 發起的一項以青少年為中心的計劃，為 9-12 年級的青少年提供月經健康資訊和子宮內膜異位症教育。透過教育可以提高年輕女性對子宮內膜異位症和月經的認知。該宣傳活動鼓勵護理和醫學生及早發現和治療子宮內膜異位症，從而推動子宮內膜異位症治療市場的發展。青少年推廣計畫是子宮內膜異位症協會最重要的教育計畫之一，重點關注十幾歲的女孩，她們是子宮內膜異位症最脆弱的受害者。可以顯著減少這種疾病對您生活的影響。迄今為止，子宮內膜異位症協會已向 34 個州的數千名兒童分發了 2,577 個青少年推廣教育套件。

促性腺激素分泌釋放激素 (GnRH) 生長

促性腺激素分泌釋放激素（GnRH）由內分泌系統腦下垂體分泌，刺激濾泡刺激素和黃體激素的合成。性荷爾蒙睪固酮、雌激素和黃體酮是由這些促性腺激素分泌（荷爾蒙）產生的。性發展、性慾和生育能力取決於 GnRH。 GnRH間接促進女性生殖系統黃體酮和雌激素的內部合成。這些是主要的女性激素，對於懷孕和排卵至關重要。

人工智慧和遠端醫療在子宮內膜異位症治療的應用

近幾十年來，通訊和電腦技術已成功應用於醫療保健管理。此外，在COVID-19大流行的第二階段，這些技術被廣泛應用於常規臨床實踐，特別是在子宮內膜異位症等持續性疾病患者的治療中。由於大流行的限制，大多數尋求緩解疼痛或不孕症治療的子宮內膜異位症患者無法去醫院。這種情況增加了急性子宮內膜異位症問題的可能性，如腸阻塞、直腸出血、泌尿道出血、囊腫破裂和劇烈腹痛。

在北美，子宮內膜異位症治療市場預計將穩定成長。

北美子宮內膜異位症治療市場預計將因該地區子宮內膜異位症盛行率的增加而受到推動。例如，根據婦女健康辦公室的說法，當類似於子宮內膜或子宮內膜的組織生長在器官之外時，就會發生子宮內膜異位症。子宮內膜異位症的生長會導致月經期間腫脹和出血。超過 11% 的 15 至 44 歲美國女性可能患有子宮內膜異位症。子宮內膜異位症在 30 多歲和 40 多歲的女性中更為常見，會使懷孕變得更加困難。各種治療可以減輕症狀，也可能增加懷孕的機會。

子宮內膜異位荷爾蒙療法

荷爾蒙療法：有多種黃體素荷爾蒙療法，包括含有levonorgestrel的避孕器（Mirena、Skyla）、植入式植入（Nexplanon）、靜脈注射避孕藥（Depo-Provera）或黃體素藥丸（Camila）。
Aromatase抑制劑：一組稱為Aromatase抑制劑的藥物可透過降低體內雌激素水平來發揮作用。為了控制子宮內膜異位症，醫生可能會建議使用含有Aromatase抑制劑和黃體素的荷爾蒙避孕藥。
荷爾蒙避孕藥、避孕藥、貼片和避孕環有助於調節導致子宮內膜組織每月堆積的荷爾蒙。在某些情況下，使用荷爾蒙避孕藥，尤其是連續週期療法，可以減少或消除不適。

FDA核准子宮內膜異位症治療藥物

2023年6月，葛蘭素史克公司表示，錯配修復缺陷（dMMR）/微衛星不穩定性高（MSI-H）與化療合併治療原發性晚期或復發性子宮內膜癌成年患者的Gemperli （dostallimab）的補充生技藥品核准申請（sBLA））已被美國食品藥物管理局（FDA）接受。
2022 年 8 月，Myovant Sciences 和輝瑞公司宣布 MYFEMBREE(R)（relugolix 40mg、雌二醇 1mg、醋酸炔諾酮 0.5mg）已被批准用於治療閉經女性中度至重度子宮內膜異位症相關疼痛。美國藥物管理局 (FDA) 宣布，該藥物已獲得美國食品藥物管理局(FDA)核准作為每日一次、一粒的治療藥物。治療方法永續長達 24 個月。

A common yet excruciating condition that can interfere with individuals' everyday lives is endometriosis. When endometriosis is present, tissue that resembles the uterine lining grows in additional places in one's pelvis and abdomen. Endometriosis can cause painful, prolonged periods in addition to reproductive issues. Medication or surgery is often used to treat endometriosis.

Growing prevalence of endometriosis

According to the World Health Organization, approximately 10% (190 million) of women and adolescents of reproductive age worldwide suffer from endometriosis. Extreme pelvic discomfort is a common side effect of endometriosis, particularly during menstruation. Some also experience pain when using the restroom or having intercourse. A few individuals struggle with conception. Regardless of their social standing or cultural background, endometriosis is a complicated illness that affects a large number of women worldwide from the time of their menarche until menopause. Endometriosis therapy often focuses on managing symptoms because there is presently no recognized cure for the condition. This has led to the growth of the endometriosis treatment industry.

Rising endometriosis awareness programs

Various government association is focusing on building programs to provide people with the required knowledge about endometriosis. For instance, The ENPOWR Project is EndoFound's youth-focused effort to provide menstrual health information and endometriosis education to teenagers in grades 9 through 12. Young women's understanding of endometriosis and dysmenorrhea can be improved by education. The campaign encouraged nursing and medical students to seek care for endometriosis early identification and management boosting the endometriosis treatment market. The Teen Outreach Programme is one of the Endometriosis Association's most significant educational programs because it focuses on teenage girls who are the disease's most susceptible victims and can significantly lessen the disease's effects on their lives. The association has given out 2,577 Teen Outreach instructional kits to thousands of children throughout 34 states.

Growth of Gonadotropin-Releasing Hormone (GnRH)

Gonadotropin-releasing hormone (GnRH) is used by the pituitary gland in the endocrine system to promote the synthesis of follicle-stimulating hormone and luteinizing hormone. The sex hormones testosterone, estrogen, and progesterone are produced by these gonadotropins (hormones). Sexual development, sex drive, and fertility depend on GnRH. GnRH indirectly promotes the body's synthesis of progesterone and estrogen in the female reproductive system. These are the main female sex hormones, and they are essential for conception and ovulation.

Artificial Intelligence and Telemedicine in the Treatment of Endometriosis

Communication and computer-based technologies have been successfully applied to healthcare administration in recent decades. Additionally, during the COVID-19 epidemic 2, these technologies were widely used in regular practice, particularly for the management of patients with persistent illnesses like endometriosis. Most endometriosis patients seeking treatment for pain alleviation or infertility were unable to visit hospitals due to pandemic limitations. The possibility of acute endometriosis problems such as intestinal blockage, rectal or urinary bleeding, cyst rupture, and excruciating abdominal pain was raised by this circumstance.

In North America, it is projected that the endometriosis treatment market will grow steadily.

The endometriosis treatment market in North America is anticipated to be fueled by the growing prevalence of endometriosis in the region. For instance, according to the Office on Women's Health, when tissue that resembles the lining within the uterus or womb grows outside of those organs it might lead to endometriosis. Endometriosis growths may swell and bleed throughout the menstrual period. It may affect more than 11 percent of American women between the ages of 15 and 44. It is more common in women in their 30s and 40s and may make getting pregnant more challenging. The symptoms may be controlled with a variety of treatments, which can also increase one's chances of getting pregnant.

Endometriosis Hormone Therapy

Progestin Therapy, Numerous progestin treatments, such as an intrauterine device with levonorgestrel (Mirena, Skyla), a contraceptive implant (Nexplanon), an intravenous contraceptive (Depo-Provera), or a progestin pill (Camila).
Aromatase Inhibitors, a group of medications known as aromatase inhibitors work to lower the level of estrogen in the body. To manage endometriosis, the doctor may advise using a combination hormonal contraception that combines an aromatase inhibitor with a progestin.
Hormonal Contraceptives, Birth control pills, patches, and vaginal rings assist regulate the hormones that cause the monthly accumulation of endometrial tissue. In some circumstances, using hormonal contraceptives, particularly continuous-cycle regimens, may lessen or eliminate discomfort.

FDA Approvals for Endometriosis Treatment Drugs

In June 2023, the supplemental Biologics Licence Application (sBLA) for Jemperli (dostarlimab) in combination with chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer was accepted by the US Food and Drug Administration (FDA), according to GSK plc.
In August 2022, Myovant Sciences and Pfizer Inc. announced that MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) has been approved by the U.S. Food and Drug Administration (FDA) as a once-daily, one-pill treatment for the management of moderate to severe endometriosis-related pain in premenopausal women. The treatment regimen may last up to 24 months.

Market Key Developments

In February 2022, to commercialize and market Linzagolix, an oral GnRH antagonist, ObsEva SA, a biopharmaceutical business researching and commercializing innovative medicines for women's health, and Theramex, a top global pharmaceutical firm specializing in women's health, have entered into a licensing agreement.
In November 2021, Organon and Forendo Pharma announced that they had signed a legally binding agreement under which Organon would acquire Forendo, a clinical-stage pharmaceutical firm that specializes in cutting-edge therapies for women's health.

Segmentation:

By Treatment Type

Pain Medication
Hormone Therapy

By Drug Class

NSAIDs
Oral Contraceptive
Others

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE

5.1. Introduction
5.2. Pain Medication
5.3. Hormone Therapy

6. ENDOMETRIOSIS TREATMENT MARKET, BY DRUG CLASS

6.1. Introduction
6.2. NSAIDs
6.3. Oral Contraceptive
6.4. Others

7. ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

7.1. Introduction
7.2. Hospital Pharmacy
7.3. Retail Pharmacy
7.4. Others

8. ENDOMETRIOSIS TREATMENT MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others